Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

BI-4020

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Boehringer Ingelheim

Drug class:

EGFR inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

furmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	BI-4020 Sensitive: D – Preclinical BI-4020 Sensitive : D	BI-4020 Sensitive: D – Preclinical BI-4020 Sensitive : D
EGFR L858R + EGFR L718Q	Non Small Cell Lung Cancer	EGFR L858R + EGFR L718Q	Non Small Cell Lung Cancer	BI-4020 Resistant: D – Preclinical BI-4020 Resistant : D	BI-4020 Resistant: D – Preclinical BI-4020 Resistant : D
EGFR L858R + EGFR E709G	Non Small Cell Lung Cancer	EGFR L858R + EGFR E709G	Non Small Cell Lung Cancer	BI-4020 Resistant: D – Preclinical BI-4020 Resistant : D	BI-4020 Resistant: D – Preclinical BI-4020 Resistant : D
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	BI-4020 Sensitive: D – Preclinical BI-4020 Sensitive : D	BI-4020 Sensitive: D – Preclinical BI-4020 Sensitive : D